Urine volume to hydration volume ratio is associated with pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma. by ISONO Tetsuichiro et al.
Urine volume to hydration volume ratio is
associated with pharmacokinetics of high-dose
methotrexate in patients with primary central
nervous system lymphoma.
著者 ISONO Tetsuichiro, HIRA Daiki, MORIKOCHI Aya,
FUKAMI Tadateru, UESHIMA Satoshi, NOZAKI
Kazuhiko, TERADA Tomohiro, MORITA Shin-ya
journal or
publication title







This is an open access article under the terms of the Creative Commons
Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided
the original work is properly cited, the use is non-commercial and no modifications or adaptations are
made.




DOI: 10.1002/prp2.883  
O R I G I N A L  A R T I C L E
Urine volume to hydration volume ratio is associated with 
pharmacokinetics of high- dose methotrexate in patients with 
primary central nervous system lymphoma
Tetsuichiro Isono1  |   Daiki Hira1,2  |   Aya Morikochi1 |   Tadateru Fukami3 |   
Satoshi Ueshima2 |   Kazuhiko Nozaki3 |   Tomohiro Terada1 |   Shin- ya Morita1
This	is	an	open	access	article	under	the	terms	of	the	Creat	ive	Commo	ns	Attri	butio	n-	NonCo	mmerc	ial-	NoDerivs	License,	which	permits	use	and	distribution	in	
any	medium,	provided	the	original	work	is	properly	cited,	the	use	is	non-	commercial	and	no	modifications	or	adaptations	are	made.





































High-	dose	methotrexate	 (HD-	MTX)-	based	chemotherapy	 is	 the	 first-	line	 treatment	
for	primary	central	nervous	system	lymphoma	(PCNSL),	but	is	associated	with	severe	
adverse	effects,	 including	myelosuppression	 and	 renal	 impairment.	MTX	 is	 primar-
ily	 excreted	 by	 the	 kidneys.	 Renal	 function	 calculated	 using	 serum	 creatinine	 (Scr)	
derived	from	muscle	may	be	overestimated	in	elderly	PCNSL	patients.	Therefore,	we	
aimed	to	construct	a	population	pharmacokinetic	model	 in	PCNSL	patients	and	ex-




serum	MTX	concentrations	were	 stratified	 into	 three	groups	of	 creatine	 clearance	
(Ccr)	 (50,	75,	 and	100	ml/min)	with	 three	groups	of	 the	urine	volume	 to	hydration	
volume	(UV/HV)	ratio	(<1,	1–	2,	and	>2).	The	final	model	was	constructed	as	follows:	




HV	<1 and Ccr of 50 ml/min failed to achieve the standard values. The present results 
demonstrated	that	the	UV/HV	ratio	was	useful	for	describing	the	pharmacokinetics	
of	MTX	in	PCNSL	patients.
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1  |  INTRODUC TION
The incidence of primary central nervous system lymphoma 
(PCNSL)	has	been	increasing	in	recent	years,	accounting	for	4.9%	
of all brain tumors.1	 PCNSL	 frequently	 develops	 in	 the	 elderly,	
with	50%	of	patients	being	65	years	or	older	at	the	time	of	onset.2 
The	 first-	line	 treatment	 for	 PCNSL	 is	 high-	dose	 methotrexate	
(HD-	MTX)-	based	 chemotherapy,	 followed	 by	 whole-	brain	 irra-
diation,	 which	 has	 significantly	 increased	 median	 survival	 time,	
and	is	strongly	recommended	as	induction	therapy	for	PCNSL.3,4 
The	 rapid	 and	 high-	dose	 intravenous	 infusion	 of	 MTX	 in	 HD-	
MTX	therapy	 increases	 the	penetration	of	MTX	 into	 the	central	
nervous	 system	 via	 the	 blood-	brain	 barrier,	 resulting	 in	 stron-
ger antitumor effects in the central nervous system.5	However,	
this	treatment	is	associated	with	severe	adverse	effects,	such	as	
renal	 damage	 and	myelosuppression,	 due	 to	 increased	 systemic	
exposure.6,7	 Therefore,	 serum	 MTX	 concentrations	 need	 to	 be	
monitored	 during	 HD-	MTX	 therapy.	 To	 the	 risk	 of	 adverse	 ef-
fects,	 it	 needs	 to	 be	 below	 the	 standard	 values,	 such	 as	 10	μM	
at	24	h,	1	μM	at	48	h,	and	0.1	μM	at	72	h	after	 the	 initiation	of	
its administration.6,8	 Since	 MTX	 is	 mainly	 excreted	 by	 the	 kid-
neys,	the	evaluation	of	renal	function	is	important.	Patients	with	
PCNSL	 are	 older	 than	 those	with	 acute	 lymphoblastic	 leukemia	
(ALL)	 and	 osteosarcoma,	 whereas	 the	 efficacy	 of	 HD-	MTX	 for	





to	 the	 more	 widespread	 application	 of	 HD-	MTX	 therapy	 to	 el-
derly	 PCNSL	 patients.11 The renal function generally declines 
with	advancing	age,	and,	thus,	reduced	MTX	excretion	in	PCNSL	




muscle may be overestimated.12,13	A	population	pharmacokinetic	










many of whom are elderly.
Therefore,	 the	 purpose	 of	 the	 present	 study	 was	 to	 establish	
a	population	pharmacokinetic	model	 for	HD-	MTX	 in	patients	with	
PCNSL	 and	explore	 the	 factors	 associated	with	MTX	clearance	 in	
addition	to	Scr.
2  |  MATERIAL S AND METHODS
2.1  |  Study design
The	present	study	was	designed	as	a	single-	center,	retrospective	
observational	clinical	study	for	investigating	the	pharmacokinet-
ics	 of	 MTX.	 The	 study	 protocol	 was	 performed	 in	 accordance	
with	 the	 Declaration	 of	 Helsinki	 and	 approved	 by	 the	 Ethics	
Committee	 at	 Shiga	 University	 of	 Medical	 Science	 (Approval	
Number	 R2020-	086).	 Japanese	 adult	 inpatients	 with	 PCNSL	
who	 received	 HD-	MTX	 at	 Shiga	 University	 of	 Medical	 Science	
Hospital	between	July	2015	and	June	2020	were	enrolled	in	the	
present study. Written informed consent was waived because of 
the	 anonymous	nature	of	 the	data.	As	 an	ethical	 consideration,	
participants had been provided with the opportunity to opt out 
from this research based on written information posted on the 
homepage	 of	 Shiga	 University	 of	 Medical	 Science	 Hospital.	 To	
prevent	 renal	 impairment	 by	 MTX,	 HD-	MTX	 was	 administered	
after	 urine	 alkalinization	 with	 intravenous	 sodium	 bicarbonate.	
The	dose	of	MTX	was	fixed	at	3500	mg/m2 and administered in a 
4-	h	continuous	intravenous	infusion.	Hydration	and	alkalinization	













2.2  |  Data collection
MTX	 doses,	 serum	MTX	 concentrations,	 Scr,	 urine	 volume	 (UV),	
and the following demographics were extracted from electronic 
medical	 records	 at	 Shiga	University	 of	Medical	 Science	Hospital:	
age,	weight,	height,	gender,	hydration	volume,	the	number	of	MTX	
K E Y W O R D S
creatinine	clearance,	high-	dose	methotrexate,	hydration	volume,	population	pharmacokinetics,	
primary	central	nervous	system	lymphoma,	urine	volume
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chemotherapy	cycles,	and	concomitant	drugs	(Non-	Steroidal	Anti-	
inflammatory	Drugs	(NSAIDs),	proton	pump	inhibitors	(PPI),	leveti-
racetam	 (LEV),	 and	 calcium	channel	 blockers	 (CCB)).	 Serum	MTX	










mula	 (CG	 formula)	 based	 on	 gender,	 age,	 body	weight	 (BW),	 and	
Scr.20	The	combination	of	NSAIDs,21	PPI,22	 LEV,23 or CCB24 with 
MTX	has	been	associated	with	delayed	MTX	excretion	and	altered	
transporter activities.
2.3  |  Sampling and assays
Serum	 MTX	 concentrations	 were	 measured	 using	 the	 ABBOTT	
ARCHITECT®	 analyzer	 i1000SR	 fluorescence	 polarization	 immu-
noassay	 (Abbott	 Laboratories).	 The	 limit	 of	 quantification	 (LOQ)	
was 0.04 μM.	Serum	MTX	concentrations	below	LOQ	were	fixed	at	
0.02 μM	(LOQ/2).25,26
2.4  |  Population pharmacokinetic analysis
A	population	pharmacokinetic	analysis	was	performed	using	non-	
linear	 mixed	 effect	 modeling	 (NONMEM)	 program	 version	 7.5.0	
(Icon	Development	Solutions).	The	first-	order	conditional	estima-
tion	method	was	used	throughout	the	model-	building	procedure.	
Two-	 and	 three-	compartment	 structural	 models	 with	 an	 expo-
nential	 residual	 error	model	were	 considered.	Two-	compartment	
structural models were selected as the base model after consid-




of	 the	peripheral	 compartment	 (V2).	An	exponential	 relationship	
was	 employed	 to	model	 inter-	individual	 variability	 (IIV)	 for	 phar-
macokinetic	parameters.	Differences	between	the	observed	con-
centrations in individuals and their respective predictors were 
considered.	A	stepwise	covariate	modeling	procedure	was	 imple-




ered to be significant during the covariate screening process. The 





and	COVmedian denote the covariate of the ith patients and the median 
of	the	covariate,	and	θ1 and θ5 represent population mean estimates. 
Equation	(1)	represents	continuous	variables,	such	as	Scr	and	UV,	while	
Equation	 (2)	 denotes	 categorical	 variables,	 including	 concomitant	
drugs.	COVi = 1 means that a concomitant drug is used. The diagnostic 
criteria	 for	GOF	 included	a	decrease	 in	OFV	of	at	 least	3.841,	a	 re-
duction	 in	unexplained	 inter-	patient	variability,	 randomly	distributed	
conditional	weighted	residuals	(CWRES),	and	a	closer	relationship	be-
tween the predicted and observed concentrations. The full model was 





2.5  |  Model evaluation





non-	parametric	 bootstrap	 analysis	 to	 investigate	 the	 robustness	
of	 the	 final	model.	 In	 the	 VPC	 analysis,	 1000	 hypothetical	 data	
sets	were	simulated	by	random	sampling	using	the	NONMEM	pro-
gram.	 The	median	 and	 90%	 prediction	 interval	 of	 the	 simulated	
concentrations	were	plotted	using	OBS.	The	bootstrap	was	used	
to investigate the ability to predict data. The bootstrap method 
was	 performed	 with	 Perl-	speaks-	NONMEM	 (version	 7.5.0).27 
Individual data were randomly sampled to produce another data-
set	 with	 the	 same	 size	 as	 the	 original	 dataset.	 In	 the	 bootstrap	
analysis,	 the	median	 values	 and	 95%	 prediction	 intervals	 of	 the	
parameters estimated using 1000 replication data sets were com-
pared with population parameters obtained by the final model. 
The model was considered to be validated if no significant differ-
ences were observed.
2.6  |  Monte Carlo simulation
Monte	Carlo	simulations	were	conducted	using	the	final	population	
pharamacokinetic	model	 to	 assess	 the	 impact	 of	 the	UV/HV	 ratio	
and	Ccr	on	MTX	excretion.	Using	the	NONMEM	program,	200	MTX	
(1)Pi = θ1 ⋅ (COVi∕COVmedian)θ5
(2)Pi = θ1 ⋅ θ
COVi
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2.7  |  Statistical analysis
Data are expressed as medians unless otherwise indicated. In mul-
tiple	 comparisons	 against	 a	 control	 group,	 significant	 differences	
were	evaluated	using	the	Kruskal–	Wallis	test,	followed	by	IBM	SPSS	
Statistics	version	27.	A	probability	value	of	less	than	.01	was	consid-
ered to be significant.
3  |  RESULTS
3.1  |  Patient characteristics
Sixteen	patients	treated	with	HD-	MTX	for	49	courses	were	included	
in	 the	 population	 pharmacokinetic	 analysis.	 MTX	 concentrations	
were	measured	at	193	points	(3–	6	samples	per	course).	Eighteen	out	
of	193	points	were	below	LOQ	(0.04	μM)	and	fixed	at	half	of	LOQ	





3.2  |  Population pharmacokinetic analysis
The	time	after	dose	versus	MTX	concentrations	is	shown	in	Fig.	S1.	
It	was	not	a	one-	compartment	model	because	semi-	log	plots	were	
not	 a	 straight	 line.	After	48	and	72	h,	 some	points	 exceeded	 the	
standard	 values.	 MTX	 concentration-	time	 data	 were	 best	 de-
scribed	by	a	 two-	compartment	model	with	 first-	order	elimination	
(OFV	=	247.149).	In	addition,	since	there	were	few	blood-	sampling	
points	 (median	 of	 4	 points),	 two-	compartment	 structural	 models	
were	 selected.	 Although	 IIV	 estimation	 parameters	 (CL	 and	 V1)	
were	 not	 significant	 (OFV	=	 245.802),	 IIV	 estimation	 parameters	
(CL	and	V2,	CL	and	Q)	were	significant	(OFV	=	223.616,	222.298,	
respectively).	 Since	 the	 latter	 had	 a	 large	ω2 of Q	 (0.395),	 IIV	 es-
timation	parameters	were	CL	and	V2.	The	OFV	of	an	exponential	
error	model	was	less	(OFV	=	196.659)	than	that	of	a	combined	error	
model	with	 an	 exponential/additive	 component	 (OFV	=223.616);	
however,	ω2 of Q was >1	in	an	exponential	error	model.	The	OFV	
of	an	additional	error	model	did	not	converge.	As	described	above,	
a combined error model was selected. The model building process 
is	summarized	in	Table	2.	The	screening	of	the	different	covariates	
showed	 that	Scr,	Ccr,	 eGFR,	 age,	 and	BSA	 reduced	OFV,	 and	Ccr	
exerted	a	stronger	effect.	CL	was	markedly	influenced	by	UV,	HV,	
and	UV/HV,	 and	UV/HV	was	 significantly	 higher	 than	UV	or	HV.	
BW,	 the	 number	 of	MTX	 chemotherapy	 cycles,	 and	 concomitant	
drugs	 (NSAIDs,	PPI,	LEV,	or	CCB)	did	not	 induce	a	significant	de-
crease	 in	OFV.	The	effect	of	NSAIDs	was	not	 able	 to	be	 analyze	
because none of the patients was administered aspirin or other 
non-	steroidal	anti-	inflammatory	drugs	 in	the	present	study.	There	
were	no	 significant	 covariates	 in	 the	volume	of	distribution.	As	 a	
result,	Ccr	and	UV/HV	were	selected	and	used	as	 the	 full	model.	
Ccr	and	UV/HV	both	had	large	effects	among	the	indicators	of	renal	
function.	Ccr	 or	UV/HV	 in	 the	 full	model	was	 excluded	 from	 the	
model	one	at	a	time,	and	OFV	increased	by	more	than	6.635	from	
the	full	model;	therefore,	the	full	model	was	set	as	the	final	model.	
Although	multicollinearity	 was	 considered	 between	 Ccr	 and	 UV/
HV,	no	correlation	was	found	between	the	two	parameters	(Fig.	S2).	
Therefore,	Ccr	 and	UV/HV	were	both	 incorporated	 into	 the	 final	
model.	Covariance	between	 inter-	individual	 variability	 for	CL	and	
that	for	V2	was	27.0%,	and	the	correlation	coefficient	between	in-
dividual	CL	 and	V2	was	 .621.	 The	 final	model	was	 shown	by	 the	
following	equation:	CL	=	4.90·(Ccr/94.5)0.456·(UV/HV)0.458.


























Proton pump inhibitor 9
Levetiracetam 6
Calcium	channel	blocker 8
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model was also assessed by 1000 bootstrap resamplings. The median 
values of the bootstrap procedure were similar to the parameter esti-
mates obtained from the original dataset. The final model was further 
evaluated	using	a	VPC	analysis	(Fig.	S3).	The	VPC	analysis	generally	in-





3.4  |  Monte Carlo simulation
To	 simulate	 serum	MTX	 concentrations	 using	 the	 final	 population	




centration	in	UV/HV	<1 at 24 h decreased from 12.3 to 5.5 μM	when	
Ccr	values	changed	from	50	to	100	ml/min.	Additionally,	the	median	
predicted concentration in Ccr = 50 ml/min at 24 h decreased from 
12.3 to 4.3 μM	when	UV/HV	changed	from	<1 to >2. The median 
predicted	concentrations	in	UV/HV	>2 were significantly lower than 
those	 in	UV/HV	<1	and	UV/HV	=	1–	2	at	all	Ccr	values	 (p <	 .001).	
Furthermore,	 the	 median	 predicted	 concentrations	 in	 UV/HV	 >2 
were	below	the	standard	values	at	24	h	(10	μM),	48	h	(1.0	μM),	and	







the robustness and accuracy of the final model were acceptable.
Since	MTX	is	mainly	excreted	unchanged	from	the	kidneys,	serum	
MTX	concentrations	are	slightly	higher	in	patients	with	impaired	renal	








Other	covariates,	such	as	BSA,30	BW,18	and	age,18 have been reported 
to	affect	the	pharmacokinetics	of	MTX.	In	the	present	study,	we	also	
analyzed	BSA,	BW,	and	age	in	a	covariate	analysis,	and	age	and	BSA,	





Base model θ1 223.616
1 θ1 ⋅ (Scr∕0.65)θ5 209.894 −13.722 <.01
2 θ1 ⋅ (Age∕66)θ5 211.676 −11.94 <.01
3 θ1 ⋅ (Ccr∕94.5)θ5 184.178 −39.438 <.01
4 θ1 ⋅ (eGFR∕87.7)θ5 204.067 −19.549 <.01
5 θ1 ⋅ (BSA∕1.68)θ5 219.543 −4.073 <.05
6 θ1 ⋅ (BW∕61.5)θ5 222.654 −0.962 n.s.
7 θ1 ⋅ (UV∕4760)θ6 −69.827 −293.443 <.01
8 θ1 ⋅ (HV∕3000)θ6 −118.658 −342.274 <.01
9 θ1 ⋅ (UV∕HV)θ6 −127.322 −350.938 <.01
10 θ1 ⋅ (1 − θ7 ⋅MTXNUM) 222.951 −0.665 n.s.
11 θ1 ⋅ θ8(PPI) 223.500 −0.116 n.s.
12 θ1 ⋅ θ8(LEV) 220.667 −2.949 n.s.
13 θ1 ⋅ θ8(CCB) 220.725 −2.891 n.s.








TA B L E  2 Summarized	pharmacokinetic	
model	building	steps	(on	CL)
6 of 11  |     ISONO et al.
but	 not	 BW,	were	 significant.	However,	 since	 age	 and	 physical	 size	
were	included	in	Ccr	calculated	from	the	CG	formula,20	age	and	BSA	










Serum	MTX	 concentration	 are	 high	 in	 patients	 with	 impaired	
renal function.12,14,16	Therefore,	 the	dosage	administered	needs	to	
be	adjusted	based	on	renal	function.	Since	UV	is	an	index	of	renal	
function,	 it	 is	 included	 in	 the	 formula	 for	 inulin	 clearance	and	Ccr	
by	24-	h	urine	collection.31,32 These clearance values are generally 
not	utilized	in	clinical	practice	because	they	are	complex,	expensive,	
and inaccurate.31–	33	Therefore,	renal	function	is	often	evaluated	by	




overestimation of renal function. Previous studies suggested that 
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renal function may not be accurately evaluated.12,13 In the present 
study,	some	patients	had	Ccr	higher	than	150	ml/min.	Furthermore,	
the	 clearance	 of	MTX	 for	 a	 typical	 patient	 (Ccr	 value	 of	 94.5	ml/
min)	in	the	present	study	was	estimated	to	be	4.9	L/h	(81.7	ml/min).	
The	protein	binding	of	MTX	in	serum	has	been	reported	to	be	in	the	





consider not only Ccr but also the contribution of proximal tubular 
secretion.
The	incidence	of	PCNSL	is	high	in	the	elderly,	50%	of	whom	are	
65	years	or	older	at	the	time	of	onset.2 In consideration of brain fra-
gility	 in	elderly	patients,	a	treatment	regimen	without	whole-	brain	
irradiation has been assessed in Phase II trials.36,37 In the present 
study,	 the	majority	of	PCNSL	patients	were	elderly	with	a	median	




renal	 function,	HD-	MTX-	based	 chemotherapy	 is	 tolerable	 and	 ef-
fective	 as	 a	 remission	 induction	 therapy	 for	 PCNSL.11	Many	 pop-
ulation	 pharmacokinetic	 analyses	 of	HD-	MTX	 patients	 have	 been	
conducted	 to	 date;	 however,	 the	majority	 involved	ALL,	 osteosar-
coma,	 and	 pediatric	 cancers.10,14–	18 Only one analysis examined 
adult	 PCNSL	 patients,19 which facilitated the estimation of serum 
MTX	concentrations	in	PCNSL	patients.	However,	in	that	study,	the	
clearance	covariate	was	assessed	from	Scr,	and	renal	function	may	




ity	 of	MTX	 pharmacokinetics	 in	 addition	 to	 creatinine-	based	 renal	
function.	MTX	is	administered	with	large	volume	of	saline	hydration	
containing	sodium	bicarbonate	to	prevent	MTX	accumulation	in	the	
tubules,	 and	 serum	MTX	 concentrations	were	 shown	 to	 be	 signifi-
cantly lower in patients receiving greater hydration.38,39	Therefore,	
it	is	reasonable	to	incorporate	HV	as	a	covariate	in	the	model.	In	ad-
dition,	in	the	case	of	decreased	UV	after	administration	of	HD-	MTX,	
a	 large	volume	of	 saline	hydration	 is	 recommended	 to	 increase	UV	
and	reduce	serum	MTX	concentrations.40	HV	and	UV	are	inextrica-








be involved. This constructed descriptive model was able to represent 
Parameter




%) Median 95% CI
CL	(L/h) θ1 4.900 4.02–	5.78 23.5	(13) 4.90 4.00–	6.75
V1	(L) θ2 9.010 5.76–	12.26 — 9.08 4.31–	17.03
V2	(L) θ3 5.730 3.83–	7.63 16.1	(20) 5.59 0.77–	7.73
Q	(L/h) θ4 0.669 0.42–	0.69 — 0.63 0.043–	0.93
Ccr	on	CL θ5 0.456 0.22–	0.69 — 0.45 0.12–	0.93
UV/HV	on	CL θ6 0.458 0.39–	0.53 — 0.43 0.03–	0.54
σ	(CV)






TA B L E  3 Population	pharmacokinetic	
parameter estimates of methotrexate in 
the final model
F I G U R E  2 Impact	of	creatinine	clearance	and	the	urine	volume/
hydration volume ratio on methotrexate clearance. Correlation 
between the population mean estimates of methotrexate and 
creatinine	clearance	(Ccr)	in	the	final	model.	Blue,	black,	green,	and	
red lines indicate population mean estimates for a typical patient 


















8 of 11  |     ISONO et al.











pairment.41 Others suggest that measuring urine volume is important 
to	prevent	adverse	effects,40,42 which is supported by the results of 
the	present	study.	Further	study	may	be	needed	to	clarify	the	mecha-
nism	of	UV/HV	interaction	with	MTX	CL.	In	addition,	we	did	not	spec-
ify	 the	oral	water	 intake,	which	suggests	 that	 the	oral	water	 intake	
varies	among	individuals.	Because,	 if	the	oral	water	 intake	changes,	
the amount of water entering the body can vary greatly from patient 
to	patient	even	with	the	same	amount	of	HV,	we	should	not	 ignore	
the	 effect	 of	 the	 oral	water	 intake	 on	 clearance.	 It	 is	 necessary	 to	
F I G U R E  3 Simulations	of	serum	concentrations	of	methotrexate	at	24	h	(A),	48	h	(B),	and	72	h	(C)	after	dose	administration	in	200	
replication	data	sets	from	16	patients	administered	3500	mg/m2.	These	simulations	were	conducted	using	the	final	model.	Box-	and-	whisker	
plots	are	presented	according	to	Tukey's	style.	Open	circles	show	outliers.	Three	groups	consisted	of	patients	with	a	urine	volume	to	
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Previous studies reported the involvement of various transport-
ers	in	the	excretion	of	MTX,	and	fluctuations	in	CL	due	to	genetic	
polymorphisms.43–	45	 Many	 Japanese	 individuals	 have	 mutations	
in ABCG2 and SLCO1B1	(OATP1B1).46,47	MTX	clearance	was	found	
to be reduced in patients with SLCO1B1 mutations.43 These issues 
were	 not	 examined	 in	 the	 present	 study;	 therefore,	 further	 re-





ies demonstrated that the combined use of PPI did not affect the 
excretion	of	MTX.48	In	the	present	study,	the	combined	use	of	PPI	
did	 not	 have	 any	 significant	 effects,	 similar	 to	 LEV	 or	 CCB.	 It	 is	
important	 to	 note	 that	 the	 antiepileptic	 drug	 LEV	 did	 not	 affect	
the	clearance	of	MTX.	PCNSL	patients	often	develop	epilepsy	due	
to	 brain	 disorders,49	 requiring	 the	 administration	 of	 antiepileptic	
drugs	that	do	not	affect	MTX	clearance.
A	limitation	of	this	study	is	the	small	number	of	patients	enrolled	
(male/female;	 12/4)	 although	 the	 total	 MTX	 concentrations	 mea-
sured	was	193.	Since	no	significant	effects	of	concomitant	drugs	and	
other	factors	were	observed	in	these	patients,	further	comprehen-
sive analysis including concomitant drugs need to be conducted in a 
larger number of patients.
5  |  CONCLUSIONS
The present study demonstrated that newly constructed population 
pharmacokinetic	parameters	in	PCNSL	patients	appropriately	reflect	
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